A practicing physician's view on obesity;Az elhízásról - A gyakorló orvos szemszögébol

Orvosi Hetilap

Volumn 147, Issue 13, 2006, Pages 579-590

  Juhász, Attila ^a,b   Katona, Evelin ^a   Csongrádi, Éva ^a   Paragh, György ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b NONE   (Hungary)

Author keywords

Body mass index; LAGB; Leptin; Obesity; Orlistat; Sibutramin; Waist circumference

Indexed keywords

LEPTIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; ANOREXIGENIC AGENT; ANTIOBESITY AGENT;

ADIPOCYTE; ANTHROPOMETRY; ARTICLE; BEHAVIOR MODIFICATION; BODY HEIGHT; BODY MASS; BODY WEIGHT; CALORIC INTAKE; COMORBIDITY; DIET RESTRICTION; DIET THERAPY; ENERGY EXPENDITURE; EXERCISE; FOOD INTAKE; GASTRIC BANDING; HUMAN; HYPOTHALAMUS; LIFESTYLE MODIFICATION; MORBID OBESITY; MORTALITY; NEUROTRANSMISSION; OBESITY; PHYSICIAN ATTITUDE; RISK FACTOR; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ALGORITHM; BARIATRIC SURGERY; DECISION TREE; DRUG EFFECT; FAT INTAKE; HUNGARY; INTESTINE ABSORPTION; LIFESTYLE; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; REVIEW; THERMOGENESIS;

ALGORITHMS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BARIATRIC SURGERY; BODY MASS INDEX; DECISION TREES; DIETARY FATS; ENERGY INTAKE; EXERCISE; HUMANS; HUNGARY; INTESTINAL ABSORPTION; LIFE STYLE; OBESITY; OBESITY, MORBID; RISK FACTORS; THERMOGENESIS;

EID: 33646947365     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Anderson, J. W., Konz, E. C., Frederich, R. C. és mtsai: Long-term weight loss maintenance: a meta-analysis of US studies. Am. J. Clin. Nutr., 2001, 74, 579-584.
2. Allison, D. B., Fontaine, K. R., Manson, J. E., és mtsai: Annual deaths attributable to obesity in the United States, JAMA, 1999, 282, 1530-1538.
3. Atkins, R.: Dr. Atkins' New Diet Revolution. Avon Books, New York, NY, 1998.
4. Bray, G. A., Blackburn, G. L., Ferguson, J. M. és mtsai: Sibutramine produces dose-related weight loss. Obes Res., 1999, 7, 189-198.
5. Bray, G. A., Tartaglia, L. A.: Medicinal strategies in the treatment of obesity. Nature, 2000, 404, 672-677.
6. Bray, G. A.: Contemporary Diagnosis and Management of Obesity. Handbooks in Health Care Co., Newtown, Pennsylvania, USA, 1998.
7. Calle, E. E., Thun, M. J., Petrelli, J. M. és mtsai: Body-mass index and mortality in a prospective cohort of U.S. adults. N. Engl. J. Med., 1999, 341, 1097-1105.
8. Carai, M. A., Colombo G., Gessa, G. L.: Rimonabant: The first therapeutically relevant cannabinoid antagonist. Drug Discovery Today, 2005, 10, 693-702.
9. Chen, H., Charlat, O., Tartaglia, L. A. és mtsai: Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation int he leptin receptor gene in db/db mice. Cell, 1996, 84, 491-495.
10. Clement, K., Vaisse, C., Lahlou, N. és mtsai: A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature, 1998, 392, 398-401.
11. Dansinger M. L., Gleason, J. A., Griffith, J. L. és mtsai: Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction. JAMA, 2005, 293, 43-53.
12. Davidson, M. H., Hauptmann, J., DiGirolamo. M. és mtsai: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized, controlled trial. JAMA, 1999, 281, 235-242.
13. DeMaria, E. J.: Bariatric procedures. ACS Surgery. 2005. WebMD Inc. http://www.medscape.com/viewarticle/505012
14. Després, J-P., Golay, A., Sjöström, L., for the Rimonabant in Obesity-Lipids Study Grou: Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia. N. Engl. J. Med., 2005, 353, 2121-2134.
15. Ettinger, M. P., Littlejohn, T. W., Schwartz, S. L. és mtsai: Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA, 2003, 289, 1826-1832.
16. Finer, N., Bloom, S. R., Frost, G. S. és mtai: Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab., 2000, 2, 105-112.
17. Fujioka, K., Seaton, T. B., Rowe, E. és mtsai: Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab., 2000, 2, 175-187.
18. Galuska, D. A., Will, J. C., Serdula, M. K. és mtsai: Are health care professionals advising obese patients to lose weight? JAMA, 1999, 282, 1576-1578.
19. Heath, C., Grant, W., Marchetti, P. és mtsai: Do family physicians treat obese patients? Fam. Med., 1993, 25, 401-402.
20. Heymsfield, S. B., Greenberg, A. S., Fujioka, K. és mtsai: Recombinant leptin for weight loss in obese and lean adults. A randomized, controlled, dose-escalation trial. JAMA, 1999, 282, 1568-1575.
21. Hill, J. O., Hauptman, J., Anderson, J. W. és mtsai: Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am. J. Clin. Nutr., 1999, 69, 1108-1116.
22. Hollander, P. A., Elbein, S. C., Hirsch, I. B. és mtsai: Role of orlistat int he treatment of obese patients with type-2 diabetes: a 1-year randomized double-blind study. Diabetes Care, 1998, 21, 1288-1294.
23. Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Practical Guide. National Institutes of Health, NHLBI Obesity Education Initiative, National Heart, Lung, and Blood Institute, North American Association for the Study of Obesity. NIH Publication, Number 00-4084, October 2000.
24. James, W. P., Astrup, A., Finer, N. és mtsai: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet, 2000, 356, 2119-2125.
25. Julesz J., Laczi F.: Obesitas. A klinikai endokrinológia és anyagcsere-betegségek kézikönyve. Szerk.: Leövey András. Medicina Könyvkiadó Rt., Budapest., 2001, 753-766. old.
26. Karlsson, J., Sjostrom, L., Sullivan, M.: Swedish obese subjects (SOS) an intervention study of obesity. Two-year follow-up of health-related quality of life (HRQL) and eating behavior after gastric surgery for severe obesity. Int. J. Obes. Relat. Metab. Disord., 1998, 22, 113-126.
27. Li, Z., Maglione, M., Tu, W. és mtsai: Meta-analysis: pharmacologic treatment of obesity. Ann. Intern. Med., 2005, 142, 532-546.
28. Lowell, B. B., Spiegelman, B. M.: Towards a molecular understanding of adaptive thermogenesis. Nature, 2000, 404, 652-660.
29. Maggard, M. A., Shugarman, L., Suttorp, M. és mtsai: Meta-analysis: surgical treatment of obesity. Ann. Intern. Med., 2005, 142, 547-559.
30. McTigue, K. M., Harris, R., Hemphill, B., Lux, L., Sutton, S., Bunton, A. J., Lohr K. N.: Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med., 2003, 139, 933-949.
31. Magyar Elhízástudományi Társaság Konszenzus Konferenciája az elhízás kezelésérol. Obesitol. Hung., 2004, 1 (Suppl.), 1-105.
32. National Center for Health Statistics. NHANES 1999 Prevalence of overweight and obesity among adults: US, 1999. Hyattsville (MD): US Department of Health and Human Services, Public Health Service. Centers for Disease Control and Prevention; 1999.
33. Pharmacologic and surgical management of obesity in primar care: A clinical practice guideline from the American College of Physicians. Ann Intern. Med., 2005, 142, 525-531.
34. Poirier, B., Bidouard, J. P., Cadrouvele, C. és mtsai: The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab., 2005, 7, 65-72.
35. Purnell, J. Q.: Obesity. ACP Medicine, 2005, © 2005 WebMD Inc.
36. Reisin, E., Abel, R., Modan, M., és mtsai: Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N. Engl. J. Med., 1978, 298, 1-6.
37. Schwartz, M. W., Woods, S. C., Portej, R. D. és mtsai: Central nervous system control of food intake. Nature, 2000, 404, 661-671.
38. Screening for obesity in adults: recommendations and rationale. U.S. Preventive Services Task Force. Ann. Intern. Med., 2003, 139, 930-932.
39. Sjostrom, C. D., Lissner, L., Wedel, H. és mtsa: Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res., 1999, 7, 477-484.
40. Sjostrom, C. D., Peltonen, M., Wedel, H. és mtsa: Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension, 2000, 36, 20-25.
41. Sjostrom, L., Lindroos, A. K., Peltonen, M., és mtsai: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med., 2004, 351, 2683-2693.
42. Sjostrom, L., Rissanen, A., Andersen, T. és mtsai: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 1998, 352, 167-172.
43. Snow, V., Barry, P., Fitterman, N. és mtsai: Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med, 2005, 142, 525-531.
44. The World Health Report 2003 - Shaping the future. Worldf Health Organization: Geneva, 2003. (http://whqlib-doc.who.int/whr/2003/ 9241562439.pdf)
45. Útmutató - Klinikai Irányelvek Kézikönyve. Az elhízás. A Magyar Elhizístudományi Társaság konszenzuskonferenciája alapján. Medition Kiadó, Budapest, 2003.
46. Van Gaal, L. R, Rissanen, A. M., Scheen, A. J., és mtsai RIO-Europe Study Group: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 2005, 365, 1389-1397.
47. Very low-caloric diets. National Task Force on the Prevention and Treatment of Obesity, National Institutes of Health. JAMA, 1993, 270, 967-974.
48. Wadden, T. A., Foster, G. D., Letizia, K. A.: One-year behavioral treatment of obesity: comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy. J. Consult. Clin., 1994, 62, 165-171.
49. Wing, R. R., Koeske, R., Epstein, L. H. śs mtsai: Long-term effects of modest weight loss in type II diabetic patients. Arch. Intern. Med., 1987, 147, 1749-1753.
50. Wolf A. M., Colditz, G. A.: The cost of obesity: the US perspective. Pharmacoeconomics, 1994, 5 (Suppl), 34- 37.
51. Wood, P. D., Stefanick, M. L., Dreon, D. M. és mtsai: Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N. Engl. J. Med., 1988, 319, 1173-1179.
52. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a World Health Organization Consultation. Geneva, Switzerland: World Health Organization; 2000; 256. WHO Obesity Technical Report Series, No. 894.
53. Yancy, W. S. Jr., Olsen, M. K., Guyton, J. R. śe mtsai: A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann. Intern. Med., 2004, 140, 769-777.
54. Yanovski, S. Z., Yanovski, J. A.: Obesity. N. Engl. J. Med., 2002, 346, 591-602.
55. Zhang, F., Basinski, M., Beals, J. és mtsai: Crystal structure of the obese protein leptin-E 100. Nature, 1997, 387, 206-209.
56. Zhang, Y., Proenca, R., Maffei, M. és mtsai: Positional cloning of the mouse obese gene and its human homologue. Nature, 1994, 372, 425-432.